Alembic Pharmaceuticals rose 4.13% to Rs 402.70 at 14:30 IST on BSE after the company's consolidated net profit rose 25.35% to Rs 77.27 crore on 12.46% rise in total income to Rs 547.22 crore in Q2 September 2014 over Q2 September 2013.
The company announced Q2 results during market hours today, 20 October 2014.
Meanwhile, the BSE Sensex was up 316.66 points or 1.23% at 26,430.96.
On BSE, so far 1 lakh shares were traded in the counter, compared with an average volume of 65,332 shares in the past one quarter.
The stock hit a high of Rs 411 and a low of Rs 390 so far during the day. The stock hit a record high of Rs 449.70 on 16 September 2014. The stock hit a 52-week low of Rs 167.50 on 18 October 2013.
The stock had underperformed the market over the past one month till 17 October 2014, falling 4.47% compared with 1.96% fall in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 15.15% as against Sensex's 2.14% rise.
The mid-cap pharma firm has an equity capital of Rs 37.70 crore. Face value per share is Rs 2.
Alembic Pharmaceuticals' profit before tax rose 19% to Rs 95.70 crore in Q2 September 2014 over Q2 September 2013. EBITDA (earnings before interest, taxes, depreciation and amortization) margin stood at 19.7% at Rs 108.30 crore in Q2 September 2014 compared with EBITDA margin of 19% to Rs 92.70 crore in Q2 September 2013.
The India branded formulations business sales rose 18% to Rs 275.50 crore in Q2 September 2014 over Q2 September 2013. Specialty and acute segments grew by 18% and 17% respectively in Q2 September 2014 over Q2 September 2013.
International generic formulation posted growth of 9% to Rs 123.40 crore in Q2 September 2014 over Q2 September 2013.
The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and intermediates.
Powered by Capital Market - Live News
